|
Studies investigating tissue angiogenic and angiostatic parameters in experimental models of pulmonary fibrosis |
||||
| Investigator (year) |
Model |
Studied Parameters |
Summary |
Limitations |
|
|
||||
| Keane et al. 61(1999) |
BPF |
MIP-2 |
Increased levels of MIP-2 in BPF mice / Inhibition of angiogenesis and fibrosis with neutralizing Abs |
Model not representative of IPF |
| Keane et al. 62(1999) |
BPF |
CXCL10 |
Decreased CXCL10 levels / CXCL10 administration reduced BPF and angiogenic response |
Model not representative of IPF |
| Jiang et al. 65 (2004) |
BPF |
CXCR3 |
Regulation of BPF by CXCR3 |
Model not representative of IPF / Incomplete analysis of angiogenic network |
| Tager et al. 78 (2004) |
BPF |
CXCL10 |
Inhibition of BPF by CXCL10 |
Model not representative of IPF / Incomplete analysis of angiogenic network |
| Burdick et al. 63 (2005) |
BPF |
CXCL11 |
Systemic administration of CXCL11 inhibited BPF by altering aberrant vascular remodeling |
Model not representative of IPF / Incomplete analysis of angiogenic network |
| Belperio et al. 52 (2005) |
Murine BOS |
CXCL1, 2, 3 CXCR2, VEGF |
Increased CXCR2/CXCR2 ligands' levels / Unchanged levels of VEGF / Neutralization of CXCR2 attenuated angiogenesis and BOS |
Model has heterotopic positioning and discounts influence of adjacent airway mucosa |
| Hamada et al. 64 (2005) |
BPF |
VEGF, sflt-1 |
Anti-VEGF gene therapy attenuates lung injury and fibrosis in BPF mice |
Model not representative of IPF / Incomplete analysis of angiogenic network |
|
Abbreviations: BPF: Bleomycin-induced pulmonary fibrosis, IPF: Idiopathic pulmonary fibrosis, VEGF: Vascular endothelial growth factor | ||||
Tzouvelekis et al. Respiratory Research 2006 7:82 doi:10.1186/1465-9921-7-82 |
||||